JCR Pharmaceuticals Co., Ltd. (4552.T)
JPY 610.0
(-0.81%)
JPY 610.0
(-0.81%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 31.25 Billion JPY | 22.76% |
| 2022 | 25.45 Billion JPY | -37.33% |
| 2021 | 40.62 Billion JPY | 82.38% |
| 2020 | 22.27 Billion JPY | 31.95% |
| 2019 | 16.88 Billion JPY | 1.73% |
| 2018 | 16.59 Billion JPY | 14.7% |
| 2017 | 14.46 Billion JPY | 17.1% |
| 2016 | 12.35 Billion JPY | 12.52% |
| 2015 | 10.97 Billion JPY | -1.22% |
| 2014 | 11.11 Billion JPY | 12.68% |
| 2013 | 9.86 Billion JPY | 8.84% |
| 2012 | 9.06 Billion JPY | 4.99% |
| 2011 | 8.63 Billion JPY | -6.48% |
| 2010 | 9.23 Billion JPY | -9.9% |
| 2009 | 10.24 Billion JPY | 20.15% |
| 2008 | 8.52 Billion JPY | 5.96% |
| 2007 | 8.04 Billion JPY | 40.53% |
| 2006 | 5.72 Billion JPY | 20.12% |
| 2005 | 4.76 Billion JPY | 7.23% |
| 2004 | 4.44 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 6.25 Billion JPY | 47.02% |
| 2024 Q1 | 5.85 Billion JPY | 31.54% |
| 2023 Q3 | 6.9 Billion JPY | -36.93% |
| 2023 Q4 | 5.95 Billion JPY | -13.73% |
| 2023 FY | 31.25 Billion JPY | 22.76% |
| 2023 Q1 | 7.44 Billion JPY | 31.54% |
| 2023 Q2 | 10.94 Billion JPY | 47.02% |
| 2022 Q4 | 5.66 Billion JPY | -37.47% |
| 2022 FY | 25.45 Billion JPY | -37.33% |
| 2022 Q1 | 6.67 Billion JPY | -7.02% |
| 2022 Q2 | 4.07 Billion JPY | -38.98% |
| 2022 Q3 | 9.05 Billion JPY | 122.3% |
| 2021 Q4 | 7.17 Billion JPY | -24.82% |
| 2021 Q3 | 9.54 Billion JPY | -41.11% |
| 2021 FY | 40.62 Billion JPY | 82.38% |
| 2021 Q1 | 7.68 Billion JPY | -11.21% |
| 2021 Q2 | 16.2 Billion JPY | 110.81% |
| 2020 Q3 | 6.17 Billion JPY | 62.97% |
| 2020 Q4 | 8.66 Billion JPY | 40.24% |
| 2020 FY | 22.27 Billion JPY | 31.95% |
| 2020 Q1 | 3.64 Billion JPY | -22.23% |
| 2020 Q2 | 3.78 Billion JPY | 3.84% |
| 2019 Q3 | 4.12 Billion JPY | -8.64% |
| 2019 Q2 | 4.51 Billion JPY | 27.25% |
| 2019 Q1 | 3.54 Billion JPY | -37.45% |
| 2019 FY | 16.88 Billion JPY | 1.73% |
| 2019 Q4 | 4.69 Billion JPY | 13.75% |
| 2018 FY | 16.59 Billion JPY | 14.7% |
| 2018 Q2 | 4.18 Billion JPY | 35.14% |
| 2018 Q3 | 3.64 Billion JPY | -12.98% |
| 2018 Q4 | 5.67 Billion JPY | 55.78% |
| 2018 Q1 | 3.09 Billion JPY | -10.86% |
| 2017 Q2 | 4.51 Billion JPY | 50.77% |
| 2017 FY | 14.46 Billion JPY | 17.1% |
| 2017 Q4 | 3.47 Billion JPY | -0.34% |
| 2017 Q3 | 3.48 Billion JPY | -22.8% |
| 2017 Q1 | 2.99 Billion JPY | -11.6% |
| 2016 Q2 | 3.39 Billion JPY | 31.92% |
| 2016 Q1 | 2.57 Billion JPY | 1.86% |
| 2016 FY | 12.35 Billion JPY | 12.52% |
| 2016 Q4 | 3.38 Billion JPY | 12.79% |
| 2016 Q3 | 3 Billion JPY | -11.49% |
| 2015 Q1 | 2.52 Billion JPY | -16.55% |
| 2015 Q4 | 2.52 Billion JPY | -3.67% |
| 2015 FY | 10.97 Billion JPY | -1.22% |
| 2015 Q3 | 2.62 Billion JPY | -20.8% |
| 2015 Q2 | 3.3 Billion JPY | 31.06% |
| 2014 FY | 11.11 Billion JPY | 12.68% |
| 2014 Q2 | 2.99 Billion JPY | 26.69% |
| 2014 Q3 | 2.72 Billion JPY | -8.94% |
| 2014 Q4 | 3.02 Billion JPY | 10.88% |
| 2014 Q1 | 2.36 Billion JPY | 2.55% |
| 2013 Q3 | 2.8 Billion JPY | 14.27% |
| 2013 Q4 | 2.3 Billion JPY | -17.67% |
| 2013 Q2 | 2.45 Billion JPY | 6.3% |
| 2013 Q1 | 2.3 Billion JPY | -8.09% |
| 2013 FY | 9.86 Billion JPY | 8.84% |
| 2012 Q2 | 2.19 Billion JPY | 8.0% |
| 2012 Q4 | 2.5 Billion JPY | 8.15% |
| 2012 FY | 9.06 Billion JPY | 4.99% |
| 2012 Q1 | 2.03 Billion JPY | 1.13% |
| 2012 Q3 | 2.31 Billion JPY | 5.51% |
| 2011 Q3 | 2.21 Billion JPY | -5.09% |
| 2011 Q2 | 2.33 Billion JPY | 13.2% |
| 2011 Q1 | 2.06 Billion JPY | -7.64% |
| 2011 FY | 8.63 Billion JPY | -6.48% |
| 2011 Q4 | 2.01 Billion JPY | -9.23% |
| 2010 Q1 | 2.75 Billion JPY | 3.12% |
| 2010 Q4 | 2.23 Billion JPY | 3.07% |
| 2010 FY | 9.23 Billion JPY | -9.9% |
| 2010 Q3 | 2.16 Billion JPY | 4.89% |
| 2010 Q2 | 2.06 Billion JPY | -25.07% |
| 2009 Q3 | 3.33 Billion JPY | 68.41% |
| 2009 Q4 | 2.67 Billion JPY | -19.65% |
| 2009 FY | 10.24 Billion JPY | 20.15% |
| 2009 Q2 | 1.97 Billion JPY | -12.55% |
| 2009 Q1 | 2.26 Billion JPY | -6.49% |
| 2008 Q4 | 2.41 Billion JPY | -5.36% |
| 2008 FY | 8.52 Billion JPY | 5.96% |
| 2008 Q3 | 2.55 Billion JPY | 44.03% |
| 2008 Q2 | 1.77 Billion JPY | 0.0% |
| 2007 FY | 8.04 Billion JPY | 40.53% |
| 2006 FY | 5.72 Billion JPY | 20.12% |
| 2005 FY | 4.76 Billion JPY | 7.23% |
| 2004 FY | 4.44 Billion JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 320.62 Billion JPY | 90.253% |
| Astellas Pharma Inc. | 1212.36 Billion JPY | 97.422% |
| Chugai Pharmaceutical Co., Ltd. | 693 Billion JPY | 95.491% |
| Ono Pharmaceutical Co., Ltd. | 375.54 Billion JPY | 91.679% |
| Santen Pharmaceutical Co., Ltd. | 163.87 Billion JPY | 80.93% |
| Daiichi Sankyo Company, Limited | 1181.79 Billion JPY | 97.356% |
| Otsuka Holdings Co., Ltd. | 1407.34 Billion JPY | 97.779% |
| Perseus Proteomics Inc. | 87.68 Million JPY | -35540.075% |